Objective: to investigate the efficacy and safety of recombinant human endostatin in combination with endovascular interventional therapy in advanced lung cancer with resistance to conventional chemotherapy and radiotherapy.Methods:44 patients with advanced lung cancer refractory to chemotherapy and radiotherapy were randomly divided into two groups. Treatment group received recombinant human endostatin transarterial infusion combined with interventional chemoembolization, while control group received with chemoembolization alone. The efficacy and quality of life were evaluated after 2 cycles. Toxicities were evaluated after 1 cycle.Results: The response rate in treatment group was signiifcantly higher than that in control group(31.8% vs 63.6%,P<0.05). The disease control rate in treatment group and control group were 86.3% and 95.4%, respectively. No severe embolization complications occurred. The toxic effects of two groups were hematologic toxicity and gastrointestinal reactions. Leukopenia and thrombocytopenia were predominant in hematologic toxicity.There was no statistical signiifcance between the toxic incidence rates of two groups.Conclusions: recombinant human endostatin combined with endovascular interventional therapy in advanced lung cancer with resistance to conventional chemotherapy and radiotherapy could improve the clinical efifcacy effectively, without increasing toxic effects. It may be worthy of further clinical investigation.%目的:评价动脉内灌注重组人血管内皮抑制素联合支气管动脉介入化疗栓塞治疗临床难治性晚期肺癌的有效性和安全性.方法:临床放化疗失败的44例晚期肺癌患者随机分为治疗组和对照组.对照组22例仅接受常规介入化疗栓塞治疗,治疗组22例患者除接受常规介入化疗栓塞外,术中化疗药物灌注加用重组人血管内皮抑制素治疗.治疗每2周期后评价疗效和生活质量,每周期后评价毒副反应.结果:对照组客观有效率为31.8%,疾病控制率为86.3%;治疗组客观有效率为59.1%,疾病控制率为95.4%.治疗组客观有效率高于对照组,两组间差异有统计学意义.对照组和治疗组生活质量改善率分别为45.5%和68.2%,两组改善率比较差异无统计学意义.无严重介入栓塞并发症发生,化疗相关毒副反应常见血液学毒性和消化道反应,血液学毒性以白细胞和血小板减少为主,两组毒副反应发生比较,差异无统计学意义.结论:重组人血管内皮抑制素联合血管介入化疗栓塞能提高难治性晚期肺癌客观有效率,且不增加化疗毒副反应,具有重要的临床价值.
展开▼
